Gut Microbiota Manipulation as a Tool for Colorectal Cancer Management: Recent Advances in Its Use for Therapeutic Purposes

International Journal of Molecular Sciences

MariaRita Giuffrè¹  Francesco Strati¹  Angélica Díaz-Basabe¹  Federica Facciotti¹  Federica Perillo¹  Georgia Lattanzi¹  Chiara Amoroso¹ 

[1] Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, 20139 Milan, Italy;

关键词: colorectal cancer;    gut microbiome;    live biotherapeutic products;   

DOI  :  10.3390/ijms21155389

来源: DOAJ

【 摘 要 】

Colorectal cancer (CRC) is a multifaceted disease influenced by both environmental and genetic factors. A large body of literature has demonstrated the role of gut microbes in promoting inflammatory responses, creating a suitable microenvironment for the development of skewed interactions between the host and the gut microbiota and cancer initiation. Even if surgery is the primary therapeutic strategy, patients with advanced disease or cancer recurrence after surgery remain difficult to cure. Therefore, the gut microbiota has been proposed as a novel therapeutic target in light of recent promising data in which it seems to modulate the response to cancer immunotherapy. The use of microbe-targeted therapies, including antibiotics, prebiotics, live biotherapeutics, and fecal microbiota transplantation, is therefore considered to support current therapies in CRC management. In this review, we will discuss the importance of host−microbe interactions in CRC and how promoting homeostatic immune responses through microbe-targeted therapies may be useful in preventing/treating CRC development.

【 授权许可】

Unknown